RANITIDINE HYDROCHLORIDE

Search structure


Trade Names:	RANITIDINE HYDROCHLORIDE ZANTAC ZANTAC 150 ZANTAC 25 ZANTAC 300 ZANTAC 75 ZANTAC IN PLASTIC CONTAINER
Synonyms:	AH 19065 AH-19065 Azantac Dumoran Gavilast Gavilast-p Histac Raciran 150 Raciran 300 Ranicalm Raniplex Ranitic Ranitidine hcl Ranitidine hydrochloride Ranitil Rantec Ranzac Taladine Vivatak Zaedoc 150 Zaedoc 300 Zantac Zantac 150 Zantac 25 Zantac 300 Zantac 75 Zantac 75 dissolve Zantac 75 relief Zantac 75 relief dissolve
Status:	Approved (1983)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	BK76465IHM
Parent Compound:	RANITIDINE

Structure


InChI Key	GGWBHVILAJZWKJ-UHFFFAOYSA-N
Smile	CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1.Cl
InChI	InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3;/h4-5,9,14-15H,6-8,10H2,1-3H3;1H

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C13H23ClN4O3S
Molecular Weight	350.87
AlogP	1.46
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	10.0
Polar Surface Area	83.58
Molecular species	NEUTRAL
Aromatic Rings	1.0
Heavy Atoms	21.0

Pharmacology

Action	Mechanism of Action	Reference
ANTAGONIST	Histamine H2 receptor antagonist	FDA

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference
HIV Infections	2	D015658	ClinicalTrials

Related Entries

Parent

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	15.18
Gastrointestinal disorders	14.06
Injury, poisoning and procedural complications	10.81
Skin and subcutaneous tissue disorders	7.31
Nervous system disorders	6.81
Respiratory, thoracic and mediastinal disorders	5.79
Immune system disorders	5.47
Vascular disorders	4.84
Cardiac disorders	4.68
Investigations	4.61
Psychiatric disorders	4.0
Musculoskeletal and connective tissue disorders	3.17
Product issues	2.09

Cross References

Resources	Reference
ChEMBL	CHEMBL2110372
FDA SRS	BK76465IHM
PubChem	47909

CONTENTS